FDA Approves MM-398, T-VEC, and Trabectedin, New Pembrolizumab Data, and More

FDA Approves MM-398, T-VEC, and Trabectedin, New Pembrolizumab Data, and More

Laura Jones reports on the FDA approvals of MM-398 for gemcitabine-refractory metastatic pancreatic cancer, T-VEC for advanced melanoma, and trabectedin in advanced soft tissue sarcomas plus new phase II/III data for pembrolizumab in lung cancer and a start of a rolling submission for cabozantinib in renal call carcinoma.